Immuron Ltd (IMRN)

$2.2

-0.03

(-1.35%)▲

Market is closed - opens 7 PM, 14 Oct 2024

Performance

  • $2.05
    $2.25
    $2.20
    downward going graph

    6.82%

    Downside

    Day's Volatility :8.89%

    Upside

    2.22%

    downward going graph
  • $1.48
    $5.96
    $2.20
    downward going graph

    32.68%

    Downside

    52 Weeks Volatility :75.15%

    Upside

    63.09%

    downward going graph

Returns

PeriodImmuron LtdIndex (Russel 2000)
3 Months
-3.51%
0.0%
6 Months
-16.98%
0.0%
1 Year
21.55%
0.0%
3 Years
-41.33%
-20.8%

Highlights

Market Capitalization
12.5M
Book Value
$0.06
Earnings Per Share (EPS)
-0.82
PEG Ratio
0.0
Wall Street Target Price
5.01
Profit Margin
-141.49%
Operating Margin TTM
-131.96%
Return On Assets TTM
-17.37%
Return On Equity TTM
-42.92%
Revenue TTM
4.9M
Revenue Per Share TTM
0.88
Quarterly Revenue Growth YOY
108.60000000000001%
Gross Profit TTM
1.7M
EBITDA
-5.2M
Diluted Eps TTM
-0.82
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
0.0
EPS Estimate Next Year
0.0
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Analyst Forecast

What analysts predicted

Upside of 127.73%

Current $2.20
Target $5.01

Company Financials

FY19Y/Y Change
Revenue
1.7M
↑ 29.55%
Net Income
-3.2M
↑ 54.26%
Net Profit Margin
-194.55%
↓ 31.17%
FY20Y/Y Change
Revenue
1.7M
↑ 5.49%
Net Income
-2.0M
↓ 37.46%
Net Profit Margin
-115.33%
↑ 79.22%
FY21Y/Y Change
Revenue
111.3K
↓ 94.21%
Net Income
-6.4M
↑ 189.12%
Net Profit Margin
-5.8K%
↓ 5645.72%
FY22Y/Y Change
Revenue
537.9K
↑ 424.91%
Net Income
-1.8M
↓ 69.15%
Net Profit Margin
-338.62%
↑ 5422.43%
FY23Y/Y Change
Revenue
1.2M
↑ 135.85%
Net Income
-2.5M
↑ 46.14%
Net Profit Margin
-209.81%
↑ 128.81%
FY24Y/Y Change
Revenue
4.9M
↑ 171.67%
Net Income
-6.9M
↑ 83.2%
Net Profit Margin
-141.49%
↑ 68.32%
Q4 FY22Q/Q Change
Revenue
412.1K
-
Net Income
-610.2K
-
Net Profit Margin
-148.08%
-
Q1 FY23Q/Q Change
Revenue
407.8K
↑ 0.0%
Net Income
-603.9K
↑ 0.0%
Net Profit Margin
-148.08%
↑ 0.0%
Q2 FY23Q/Q Change
Revenue
791.2K
↑ 92.91%
Net Income
-696.4K
↑ 14.66%
Net Profit Margin
-88.01%
↑ 60.07%
Q4 FY23Q/Q Change
Revenue
2.4M
↑ 100.0%
Net Income
-2.1M
↑ 100.0%
Net Profit Margin
-88.01%
↑ 0.0%
Q2 FY24Q/Q Change
Revenue
2.5M
↑ 8.14%
Net Income
-4.9M
↑ 134.6%
Net Profit Margin
-190.94%
↓ 102.93%
Q3 FY24Q/Q Change
Revenue
2.5M
↑ 0.0%
Net Income
-4.9M
↑ 0.0%
Net Profit Margin
-190.94%
↑ 0.0%
FY19Y/Y Change
Total Assets
5.9M
↓ 7.37%
Total Liabilities
841.1K
↑ 50.69%
FY20Y/Y Change
Total Assets
4.3M
↓ 27.56%
Total Liabilities
385.1K
↓ 53.88%
FY21Y/Y Change
Total Assets
20.7M
↑ 336.19%
Total Liabilities
884.4K
↑ 107.44%
FY22Y/Y Change
Total Assets
17.5M
↓ 8.12%
Total Liabilities
1.2M
↑ 44.94%
FY23Y/Y Change
Total Assets
14.8M
↓ 11.54%
Total Liabilities
1.6M
↑ 41.28%
FY24Y/Y Change
Total Assets
15.5M
↓ 29.28%
Total Liabilities
2.8M
↑ 19.79%
Q4 FY22Q/Q Change
Total Assets
14.8M
-
Total Liabilities
1.6M
-
Q1 FY23Q/Q Change
Total Assets
14.7M
↑ 0.0%
Total Liabilities
1.6M
↑ 0.0%
Q2 FY23Q/Q Change
Total Assets
13.4M
↓ 9.58%
Total Liabilities
1.6M
↓ 0.64%
Q4 FY23Q/Q Change
Total Assets
13.3M
↑ 0.0%
Total Liabilities
1.6M
↑ 0.0%
Q2 FY24Q/Q Change
Total Assets
15.5M
↓ 21.79%
Total Liabilities
2.8M
↑ 20.56%
Q3 FY24Q/Q Change
Total Assets
15.5M
↑ 0.0%
Total Liabilities
2.8M
↑ 0.0%
FY19Y/Y Change
Operating Cash Flow
-1.2M
↓ 49.01%
Investing Cash Flow
-1.4K
↓ 62.23%
Financing Cash Flow
1.4M
↓ 52.68%
FY20Y/Y Change
Operating Cash Flow
-2.2M
↑ 74.99%
Investing Cash Flow
-595.0
↓ 56.97%
Financing Cash Flow
798.0K
↓ 44.09%
FY21Y/Y Change
Operating Cash Flow
-3.1M
↑ 29.59%
Investing Cash Flow
2.0K
↓ 397.92%
Financing Cash Flow
20.2M
↑ 2188.79%
FY22Y/Y Change
Operating Cash Flow
-1.8M
↓ 37.52%
Investing Cash Flow
8.3K
↑ 355.98%
Financing Cash Flow
-29.8K
↓ 100.16%
FY23Y/Y Change
Operating Cash Flow
-1.7M
↑ 1.83%
Investing Cash Flow
-1.8M
↓ 22433.47%
Financing Cash Flow
-30.0K
↑ 5.23%
Q4 FY22Q/Q Change
Operating Cash Flow
-541.0K
↑ 61.61%
Investing Cash Flow
-878.6K
↑ 0.0%
Financing Cash Flow
-7.8K
↑ 7.8%
Q1 FY23Q/Q Change
Operating Cash Flow
-535.4K
↑ 0.0%
Investing Cash Flow
-5.9K
↓ 99.32%
Financing Cash Flow
-7.7K
↑ 0.0%
Q2 FY23Q/Q Change
Operating Cash Flow
-673.1K
↑ 24.99%
Investing Cash Flow
-5.9K
↑ 0.0%
Financing Cash Flow
-7.8K
↓ 0.01%

Technicals Summary

Sell

Neutral

Buy

Immuron Ltd is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Immuron Ltd
Immuron Ltd
-18.11%
-16.98%
21.55%
-41.33%
-29.03%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-12.78%
12.27%
21.13%
86.55%
232.53%
Novo Nordisk A/s
Novo Nordisk A/s
-12.16%
-3.59%
19.82%
145.88%
361.43%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
8.63%
91.46%
72.01%
39.76%
259.26%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
0.64%
21.48%
30.9%
167.3%
177.5%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Immuron Ltd
Immuron Ltd
NA
NA
0.0
0.0
-0.43
-0.17
NA
0.06
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.88
26.88
1.38
45.01
0.17
0.08
NA
261.41
Novo Nordisk A/s
Novo Nordisk A/s
40.83
40.83
1.8
3.37
0.89
0.23
0.01
25.24
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-2.38
-15.01
0.02
NA
-0.02
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
0.58
0.33
-0.03
0.13
NA
57.26
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Immuron Ltd
Immuron Ltd
NA
$12.5M
-29.03%
NA
-141.49%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$110.1B
232.53%
26.88
32.04%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$523.9B
361.43%
40.83
34.84%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$36.5B
259.26%
NA
-3.11%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$124.3B
177.5%
32.84
-4.74%

Insights on Immuron Ltd

  • Vs ALNY

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 72.0% return, outperforming this stock by 50.5%

  • Vs VRTX

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 39.8% return, outperforming this stock by 81.1%

Institutional Holdings

  • Morgan Stanley - Brokerage Accounts

    0.09%

  • Rhumbline Advisers

    0.08%

  • Stephens Consulting LLC

    0.03%

Company Information

immuron ltd is a publicly listed australian biopharmaceutical company focused on oral immunotherapy utilizing polyclonal antibody products that target the human gut immune system and gut microbiome. immuron’s technology platform is capable of developing and producing an orally stable therapeutic as a potential ‘oral targeted therapy’ for various immune mediated and inflammatory disorders, among them: non-alcoholic steatohepatitis (nash) diabetes, colitis, arthritis, inflammatory bowel diseases (ibd), irritable bowel syndrome (ibs), liver fibrosis and other chronic disorders in which the immune system plays a key role in thier pathogenesis. these disorders represent areas of growing and unmet medical need, where oral targeted therapy drugs could offer significant advantages due to the lack of absorption and the high safety profile. immuron has one marketed product, which provides proof of concept for its oral immune technology platform, and a pipeline of products at various stages of cl

Organization
Immuron Ltd
Employees
7
CEO
Dr. Jerry Kanellos Ph.D.
Industry
Health Technology

Discover More

FAQs